A Phase 2 interventional study of APD334 in Primary Biliary Cholangitis, sponsored by Arena Pharmaceuticals. Terminated at 9 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-24.
Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 62nd largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 38th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
Ipsen · Sites in United States
Women only
Zydus Therapeutics Inc. · Sites in United States
Ages 18+
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 18 · Phase 4 3
First in 1994; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 46 across the 65 interventional studies, 430 across the 17 observational. Of the 61 that completed or were terminated, 33 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Arena Pharmaceuticals, one of the names counted as Pfizer. Under that name alone:
Arena Pharmaceuticals is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Pfizer has 2 studies filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis, Biliary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06427395Phase 3Zydus Therapeutics Inc.Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | 2027-04-18 |
| NCT06825559Zydus Therapeutics Inc.Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | 2026-12-31 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07631442Stanford UniversityUsing Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC) | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).
Key Inclusion Criteria:
Males or females aged 18 to 80 years (inclusive) at the time of screening, with confirmed Primary Biliary Cholangitis (PBC) diagnosis based upon at least 2 of 3 criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
APD334 active treatment for 24 weeks.
Drug: APD334
APD334 active treatment for 24 weeks.
Also known as: etrasimod
Change in Serum Alkaline Phosphatase (ALP) Concentration
Reduction in ALP concentration is a surrogate marker of slower disease progression.
Time frame: Baseline, Week 24
Number of Participants With Adverse Events
Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.
Time frame: Up to Week 26
Change in Serum ALP Concentration
Reduction in ALP concentration is a surrogate marker of slower disease progression.
Time frame: Baseline, Week 12
Pharmacokinetic Parameters of Etrasimod, and Its Metabolites
Time frame: Up to Week 24
Exploratory - Change in Complete Blood Count
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Incidence of Fatigue as Assessed by Peripheral Biliary Cholangitis (PBC-40) Scale
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Incidence of Pruritus as Assessed by 5-Dimensions (5-D) Itch Scale
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Schirmer Test Outcome
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Tear Film Break-Up Time
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum High Sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum Alanine Transaminase (ALT)
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum Aspartate Transaminase (AST)
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum Gamma-Glutamyl Transferase (GGT)
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum C4
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum Immunoglobulin
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum GP73
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Concentration of Serum Anti-Mitochondrial Antibodies (AMA)
Time frame: Baseline, Week 12, Week 24
Exploratory - Change in Quality of Life
Time frame: Baseline, Week 12, Week 24
| Milestone | APD334 |
|---|---|
| Started | 2 |
| Participants escalated to 2 mg dose of apd334 at week 12 to week 24 | 2 |
| Completed | 2 |
| Not completed | 0 |
Reduction in ALP concentration is a surrogate marker of slower disease progression.
No measurements were reported for this outcome.
Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.
| Participants | APD334 |
|---|---|
| Number of Participants With Adverse Events | 2 |
Reduction in ALP concentration is a surrogate marker of slower disease progression.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to Week 26. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| APD334 | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | APD334 |
|---|---|
| Skin rashSkin and subcutaneous tissue disorders | 1/2 |
| Urinary tract infectionInfections and infestations | 1/2 |
| Worsening right hip painMusculoskeletal and connective tissue disorders | 1/2 |
| Elevated gamma-glutamyl transferase-worseningInvestigations | 1/2 |
| Loose stoolsGastrointestinal disorders | 1/2 |
| FatigueGeneral disorders | 1/2 |
| Common cold - Upper respiratory tract infectionInfections and infestations | 1/2 |
| Elevated alkaline phosphatase-worseningInvestigations | 1/2 |
| Lower abdominal crampsGastrointestinal disorders | 1/2 |
| PruritusSkin and subcutaneous tissue disorders | 1/2 |
| Age, Categorical(Participants) | APD334 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | APD334 |
|---|---|
| Female | NA |
| Male | NA |
| Race (NIH/OMB)(Participants) | APD334 |
|---|---|
| American Indian or Alaska Native | NA |
| Asian | NA |
| Native Hawaiian or Other Pacific Islander | NA |
| Black or African American | NA |
| White | NA |
| More than one race | NA |
| Unknown or Not Reported | NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Jan 2019, 13 months.
Results were first posted in Mar 2022, 3 years 1 month after primary completion. A results delay was requested in Jan 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod